| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.26B | 2.07B | 1.86B | 1.62B | 1.26B |
| Gross Profit | 39.69M | 416.77M | 356.83M | 335.97M | 182.01M |
| EBITDA | 321.98M | 315.48M | 324.26M | 233.76M | 159.43M |
| Net Income | 69.81M | -37.81M | -71.47M | -81.30M | -47.79M |
Balance Sheet | |||||
| Total Assets | 5.43B | 4.49B | 4.58B | 4.79B | 4.58B |
| Cash, Cash Equivalents and Short-Term Investments | 114.84M | 76.70M | 43.45M | 65.05M | 81.60M |
| Total Debt | 1.59B | 1.87B | 3.02B | 2.83B | 2.50B |
| Total Liabilities | 2.07B | 2.18B | 3.12B | 3.14B | 2.75B |
| Stockholders Equity | 3.32B | 2.26B | 1.27B | 1.40B | 1.58B |
Cash Flow | |||||
| Free Cash Flow | 165.88M | 84.15M | -1.26M | 76.25M | -61.78M |
| Operating Cash Flow | 294.44M | 176.09M | 98.53M | 147.77M | 17.91M |
| Investing Cash Flow | -1.08B | -8.73M | 9.40M | -118.58M | -138.65M |
| Financing Cash Flow | 817.50M | -134.74M | -129.06M | -42.92M | 94.11M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $8.93B | 25.53 | 9.21% | 3.56% | 59.25% | 88.37% | |
74 Outperform | $14.03B | 24.47 | 11.79% | 6.11% | 13.50% | 31.56% | |
70 Outperform | $4.20B | 28.75 | 9.85% | 4.73% | 8.04% | 9.20% | |
70 Outperform | $5.15B | 32.09 | 5.59% | 6.47% | 8.12% | 75.95% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
65 Neutral | $9.95B | 125.17 | 2.50% | 2.10% | 11.81% | ― | |
64 Neutral | $6.49B | -26.11 | -5.04% | 6.56% | -6.59% | 33.35% |
On February 27, 2026, American Healthcare REIT, Inc. and its operating partnership entered into a new at-the-market equity offering sales agreement with a syndicate of major investment banks, enabling the company to sell up to $1.75 billion of common stock from time to time. Concurrently, the company terminated its prior ATM program, which still had about $230.1 million of unsold capacity, and set agent commissions at up to 2% of gross sales proceeds, with flexibility for negotiated, block, and exchange-based transactions.
The structure also allows for forward sale agreements with designated banks acting as forward purchasers, under which shares may be borrowed and sold to hedge forward exposure, with pricing adjusted for interest and expected dividends. The company plans to contribute net proceeds from any issuances and forward settlements to its operating partnership for units redeemable into common stock, to be used for general corporate purposes such as debt repayment, working capital, capital expenditures, and potential future investments, enhancing balance-sheet flexibility and funding optionality.
The most recent analyst rating on (AHR) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on American Healthcare REIT, Inc. stock, see the AHR Stock Forecast page.
American Healthcare REIT on February 26, 2026 reported GAAP net income attributable to controlling interest of $10.8 million, or $0.06 per diluted share, for the fourth quarter of 2025 and $69.8 million, or $0.42 per diluted share, for full-year 2025, alongside Normalized FFO of $0.46 and $1.72 per diluted share for the quarter and year, respectively. The company posted total portfolio same-store NOI growth of 11.8% in the fourth quarter and 14.2% for 2025, driven by its integrated senior health campuses and senior housing operating properties, which delivered same-store NOI gains exceeding 14% for the quarter and 18% for the year.
In 2025 AHR invested over $950 million in new assets across its ISHC and SHOP segments and sold two non-core properties for $3.9 million, while subsequent to year-end it acquired five additional SHOP assets for about $117.5 million in California and Missouri. As of December 31, 2025, the REIT reported a $178 million in-process development and expansion pipeline, total consolidated indebtedness of $1.54 billion, liquidity of approximately $1.14 billion and an improved Net Debt-to-Annualized Adjusted EBITDA ratio of 3.4x, underscoring a balance of aggressive growth in senior care real estate with a moderately leveraged balance sheet.
The most recent analyst rating on (AHR) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on American Healthcare REIT, Inc. stock, see the AHR Stock Forecast page.
On February 4, 2026, American Healthcare REIT disclosed that Chief Executive Officer and President Danny Prosky took a medical leave effective February 3, 2026, with Board Chairman Jeffrey T. Hanson stepping in as interim CEO and president to maintain operational continuity alongside the established leadership team. The company emphasized its seasoned executives and ongoing commitment to its strategic objectives, underscoring confidence in uninterrupted operations despite the temporary leadership change.
The most recent analyst rating on (AHR) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on American Healthcare REIT, Inc. stock, see the AHR Stock Forecast page.
On December 16, 2025, American Healthcare REIT, Inc. announced that its board of directors declared a quarterly distribution of $0.25 per share for the fourth quarter of 2025, payable in cash on or about January 16, 2026, to shareholders of record as of December 31, 2025. This distribution reflects an annualized rate of $1.00 per share, indicating the company’s ongoing commitment to providing returns to its investors, which may enhance its attractiveness in the healthcare real estate investment sector.
The most recent analyst rating on (AHR) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on American Healthcare REIT, Inc. stock, see the AHR Stock Forecast page.